Protagonist Therapeutics, Inc. (NASDAQ:PTGX) | WebDisclosure

Basculer en Français

8295	Companies
114809	Keywords
55260	Articles
62422	Press releases

Headlines Articles Press releases Protagonist Therapeutics, Inc.

Home
Companies
Protagonist Therapeutics, Inc.

BRIEF

published on 11/19/2024 at 13:35, 1 day 20 hours ago

Protagonist Therapeutics annonce le développement d'un nouvel antagoniste de l'IL-17

Conférence Téléphonique Produits Biopharmaceutiques Thérapeutique Protagoniste Développement De Peptides Antagoniste De L'IL-17
BRIEF

published on 11/19/2024 at 13:35, 1 day 20 hours ago

Protagonist Therapeutics to Announce New IL-17 Antagonist Development

Conference Call Biopharmaceuticals Protagonist Therapeutics Peptide Development IL-17 Antagonist
PRESS RELEASE

published on 11/19/2024 at 13:30, 1 day 20 hours ago

Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate
Protagonist Therapeutics to host conference call and webcast on November 21st at 4:30 pm ET to announce oral peptide IL-17 antagonist development. Details: dial-in and webcast link provided

Conference Call Webcast Protagonist Therapeutics Oral Peptide IL-17 Antagonist Development Candidate
BRIEF

published on 11/18/2024 at 22:10, 2 days 11 hours ago

Protagonist Therapeutics annonce des résultats positifs de l'essai de phase 3 sur l'icotrokinra dans le traitement du psoriasis

Essais De Phase 3 Thérapeutique Protagoniste Johnson & Johnson Icotrokinra Psoriasis En Plaques
BRIEF

published on 11/18/2024 at 22:10, 2 days 11 hours ago

Protagonist Therapeutics Reports Positive Phase 3 Trial Results for Icotrokinra in Psoriasis

Phase 3 Trials Protagonist Therapeutics Johnson & Johnson Plaque Psoriasis Icotrokinra
PRESS RELEASE

published on 11/18/2024 at 22:05, 2 days 11 hours ago

Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113), a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor in Plaque Psoriasis
Protagonist announces positive Phase 3 ICONIC study results of icotrokinra, a first-in-class oral peptide for plaque psoriasis, achieving key endpoints and milestone payments under Johnson & Johnson collaboration

Phase 3 Plaque Psoriasis Icotrokinra Protagonist ICONIC Study
BRIEF

published on 11/07/2024 at 22:10, 13 days 11 hours ago

Mise à jour financière et étapes cliniques de Protagonist Therapeutics

Résultats Financiers Essais Cliniques Thérapeutique Protagoniste Résultats De La Phase 3 Traitement Du Psoriasis
BRIEF

published on 11/07/2024 at 22:10, 13 days 11 hours ago

Protagonist Therapeutics Financial Update and Clinical Milestones

Financial Results Clinical Trials Protagonist Therapeutics Phase 3 Results Psoriasis Treatment
PRESS RELEASE

published on 11/07/2024 at 22:05, 13 days 11 hours ago

Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Protagonist Therapeutics reports financial results and upcoming milestones for Phase 3 clinical trials in psoriasis and ulcerative colitis, Phase 3 trials in polycythemia vera, and oral peptide antagonist development candidate nomination

Ulcerative Colitis Clinical Trials Protagonist Therapeutics Polycythemia Vera Psoriasis
BRIEF

published on 11/05/2024 at 22:10, 15 days 11 hours ago

Protagonist Therapeutics présentera les données de l'étude de phase 2 lors de la réunion de l'ASH

Étude De Phase 2 Rusfertide Thérapeutique Protagoniste Réunion De L'ASH Polycythémie Vraie

Accesswire

Published on 11/21/2024 at 09:00, 42 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 9 hours 7 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 9 hours 17 minutes ago

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
Published on 11/21/2024 at 00:00, 9 hours 42 minutes ago

Swiss Mining Institute Conference Presentation
Published on 11/20/2024 at 23:00, 10 hours 42 minutes ago

Rektron Group Inc. Announces Appointment of a New Director and Provides Corporate Updates

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 09:01, 41 minutes ago

Original-Research: Netfonds AG (von NuWays AG): Buy
Published on 11/21/2024 at 08:59, 43 minutes ago

Black Friday Savings: Kling AI Offers 50% Off and Free Feature Upgrades
Published on 11/21/2024 at 08:59, 43 minutes ago

Économies Black Friday : Kling AI propose 50 % de réduction et des mises à niveau gratuites des fonctionnalités
Published on 11/21/2024 at 08:15, 1 hour 27 minutes ago

EBIT increases to EUR 55.6 million. Equity (net asset value) increases by EUR 49.3 million to EUR 300.3 million, which corresponds to 70.14 euros per share. The equity ratio rises to 94.85%.
Published on 11/21/2024 at 08:09, 1 hour 33 minutes ago

KAP HOLDS ITS GROUND IN A DIFFICULT INDUSTRY ENVIRONMENT IN THE FIRST NINE MONTHS OF 2024

Les Echos

Published on 11/21/2024 at 06:58, 2 hours 44 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 2 hours 44 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 2 hours 44 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 13 hours 35 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 14 hours 22 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE